SCHEMBL4898944

SCHEMBL4898944

CNc1c(C(=O)NCCc2ccccc2)sc2nc(C)cc(C(F)(F)F)c12

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP28 Q96RU2 10/20 0.59
USP25 Q9UHP3 7/20 0.59
MAPT P10636 2/20 0.58
RXFP1 Q9HBX9 1/20 0.58
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.50
KMT2A Q03164 1/20 0.50
CHRM4 P08173 1/20 0.49
TP53 P04637 1/20 0.49
NPC1 O15118 1/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CASP1 P29466 1/20 0.46
RAB9A P51151 1/20 0.46
CASP7 P55210 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898520 0.89 USP28 (0.72) USP28USP25MAPTRXFP1LMNA
SCHEMBL4898236 0.87 USP28 (0.60) USP28USP25MAPTRXFP1LMNA
SCHEMBL4895200 0.83 USP28 (0.65) USP28USP25MAPTRXFP1LMNA
SCHEMBL4888275 0.82 USP28 (0.74) USP28USP25MAPTLMNAPOLB
SCHEMBL22644951 0.82 USP28 (0.63) USP28USP25
SCHEMBL27708055 0.82 USP28 (0.73) USP28USP25MAPTLMNAPOLB
SCHEMBL4897966 0.82 USP28 (0.70) USP28USP25MAPTRXFP1LMNA
SCHEMBL4898867 0.82 USP28 (0.73) USP28USP25MAPTLMNAPOLB
SCHEMBL4896784 0.80 USP28 (0.71) USP28USP25MAPTLMNAPOLB
SCHEMBL4890911 0.80 USP28 (0.66) USP28USP25MAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US claimed
CN-101128470-A Novel compounds ASTRAZENECA AB (SE) 2008-02-20 CN claimed
EP-1833834-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006068618-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 WO claimed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US disclosed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US disclosed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US disclosed
CN-101128470-A Novel compounds ASTRAZENECA AB (SE) 2008-02-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306107-A1 Compounds FURIN, PCSK9, SLC10A1 USP28 4875/4885USP25 4874/4885MAPT 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.